The programme targets high‑risk, high‑reward anticancer therapeutics, while the applicant’s work focuses on addiction‑related neuropharmacology and computational drug‑screening platforms. Although the applicant has strong drug‑discovery expertise and a proven track record, the thematic mismatch reduces relevance, but the early‑career, independent‑researcher status aligns with the grant’s intent.